Patient profiles<\/strong><\/h1><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\nBernard<\/a><\/div>\n\n\n\nEvette<\/a><\/div>\n\n\n\nRalph<\/a><\/div>\n<\/div>\n\n\n\n<\/div>\n\n\n\nEvette, age 68, female<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n<\/div>![\"View](\"https:\/\/www.merckconnect.com\/verquvo\/wp-content\/uploads\/sites\/67\/2022\/12\/Image-Verquvo-Evette.png\")
<\/picture>*Not an actual patient<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n
\nHas experienced a recent increase in worsening symptoms <\/strong><\/p>\n\n\n\n<\/div>\n\n\n\nDiagnosed 18 months ago with New York Heart Association (NYHA) class III heart failure<\/strong><\/p>\n\n\n\n\n- Left ventricular ejection fraction (LVEF) 30%<\/li><\/ul><\/div>\n\n\n\n
Experienced her first heart failure (HF) hospitalization 3 months ago<\/strong><\/p>\n\n\n\n- Experienced an episode of edema and shortness of breath<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n\n\n\n
Has recently experienced worsening symptoms such as an increase in dyspnea and ankle edema<\/strong><\/h3><\/div>\n\n\n\n- Previously on sacubitril\/valsartan<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Comorbidities:<\/strong><\/h3><\/div>\n\n\n\n- Chronic kidney disease<\/li>
- eGFR = 35 mL\/min\/1.73 m2<\/sup><\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Medications:<\/strong><\/h3><\/div>\n\n\n\n- Carvedilol<\/li>
- Furosemide<\/li>
- Spironolactone<\/li>
- Valsartan<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Activity level:<\/strong><\/h3><\/div>\n\n\n\nFinds it hard to do light activity such as grocery shopping and walking short distances <\/p>\n\n\n\n
<\/div>\n\n\n\nDefinitions:<\/strong><\/h3><\/div>\n\n\n\neGFR = estimated glomerular filtration rate.<\/p>\n\n\n\n\n
<\/span><\/div><\/i><\/a>Indication<\/mark><\/strong><\/h2><\/div>\n\nVERQUVO\u00ae (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.<\/p>\n\n\n
<\/div>\n\n\nSelected Safety Information<\/mark><\/strong><\/h2><\/div>\n\n\n<\/div>\n\n\n\n \n\nWARNING: EMBRYO-FETAL TOXICITY<\/strong><\/h4><\/div>\n\n\nFemales of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.<\/strong><\/p>\n\n<\/div><\/div><\/div>\n\n\n- VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.<\/li>
- VERQUVO is contraindicated in pregnancy.<\/li>
- Embryo-Fetal Toxicity:<\/strong> Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.<\/li>
- There is a Pregnancy Surveillance Program that monitors pregnancy outcomes in women exposed to VERQUVO during pregnancy. Health care providers should report any prenatal exposure by calling 1-877-888-4231<\/span> or at https:\/\/pregnancyreporting.verquvo-us.com<\/span><\/a>.<\/li>
- In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency \u22655%, were hypotension (16% vs 15%) and anemia (10% vs 7%).<\/li>
- Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.<\/li>
- There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.<\/li><\/ul><\/div>\n\n\n<\/div>\n\n\n
Before prescribing VERQUVO, please read the accompanying Prescribing information<\/a> including the Boxed Warning about embryo-fetal toxicity. The Medication guide<\/a> also is available.<\/strong><\/p>\n\n<\/div>
Evette, age 68, female<\/strong><\/h2><\/div>\n\n\n\n<\/div>\n\n\n\n\n\n\n<\/div><\/picture>*Not an actual patient<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n
\nHas experienced a recent increase in worsening symptoms <\/strong><\/p>\n\n\n\n<\/div>\n\n\n\nDiagnosed 18 months ago with New York Heart Association (NYHA) class III heart failure<\/strong><\/p>\n\n\n\n\n- Left ventricular ejection fraction (LVEF) 30%<\/li><\/ul><\/div>\n\n\n\n
Experienced her first heart failure (HF) hospitalization 3 months ago<\/strong><\/p>\n\n\n\n- Experienced an episode of edema and shortness of breath<\/li><\/ul><\/div>\n<\/div>\n<\/div>\n\n\n\n
Has recently experienced worsening symptoms such as an increase in dyspnea and ankle edema<\/strong><\/h3><\/div>\n\n\n\n- Previously on sacubitril\/valsartan<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Comorbidities:<\/strong><\/h3><\/div>\n\n\n\n- Chronic kidney disease<\/li>
- eGFR = 35 mL\/min\/1.73 m2<\/sup><\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Medications:<\/strong><\/h3><\/div>\n\n\n\n- Carvedilol<\/li>
- Furosemide<\/li>
- Spironolactone<\/li>
- Valsartan<\/li><\/ul><\/div>\n\n\n\n<\/div>\n\n\n\n
Activity level:<\/strong><\/h3><\/div>\n\n\n\nFinds it hard to do light activity such as grocery shopping and walking short distances <\/p>\n\n\n\n
<\/div>\n\n\n\nDefinitions:<\/strong><\/h3><\/div>\n\n\n\neGFR = estimated glomerular filtration rate.<\/p>\n\n\n\n\n
<\/span><\/div><\/i><\/a>Indication<\/mark><\/strong><\/h2><\/div>\n\nVERQUVO\u00ae (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.<\/p>\n\n\n
<\/div>\n\n\nSelected Safety Information<\/mark><\/strong><\/h2><\/div>\n\n\n<\/div>\n\n\n\n \n\nWARNING: EMBRYO-FETAL TOXICITY<\/strong><\/h4><\/div>\n\n\nFemales of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.<\/strong><\/p>\n\n<\/div><\/div><\/div>\n\n\n- VERQUVO is contraindicated in patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.<\/li>
- VERQUVO is contraindicated in pregnancy.<\/li>
- Embryo-Fetal Toxicity:<\/strong> Based on data from animal reproduction studies, VERQUVO may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with VERQUVO and for at least one month after the final dose.<\/li>
- There is a Pregnancy Surveillance Program that monitors pregnancy outcomes in women exposed to VERQUVO during pregnancy. Health care providers should report any prenatal exposure by calling 1-877-888-4231<\/span> or at https:\/\/pregnancyreporting.verquvo-us.com<\/span><\/a>.<\/li>
- In a clinical trial, the most commonly observed adverse events with VERQUVO vs placebo, occurring at a frequency \u22655%, were hypotension (16% vs 15%) and anemia (10% vs 7%).<\/li>
- Concomitant use of VERQUVO with PDE-5 inhibitors is not recommended due to the potential for hypotension.<\/li>
- There are no data on the presence of vericiguat in human milk, the effects on the breastfed infant, or effects on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERQUVO, advise women not to breastfeed during treatment with VERQUVO.<\/li><\/ul><\/div>\n\n\n<\/div>\n\n\n
Before prescribing VERQUVO, please read the accompanying Prescribing information<\/a> including the Boxed Warning about embryo-fetal toxicity. The Medication guide<\/a> also is available.<\/strong><\/p>\n\n<\/div>
<\/picture>*Not an actual patient<\/p><\/figcaption><\/figure><\/div>\n<\/div>\n\n\n\n
Has experienced a recent increase in worsening symptoms <\/strong><\/p>\n\n\n\n Diagnosed 18 months ago with New York Heart Association (NYHA) class III heart failure<\/strong><\/p>\n\n\n\n\n Experienced her first heart failure (HF) hospitalization 3 months ago<\/strong><\/p>\n\n\n\n Finds it hard to do light activity such as grocery shopping and walking short distances <\/p>\n\n\n\n eGFR = estimated glomerular filtration rate.<\/p>\n\n\n\n\n VERQUVO\u00ae (vericiguat) tablets 2.5 mg, 5 mg, 10 mg is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for HF or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.<\/p>\n\n\n Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for one month after stopping treatment. Do not administer VERQUVO to a pregnant female because it may cause fetal harm.<\/strong><\/p>\n\n<\/div><\/div><\/div>\n\n\n Before prescribing VERQUVO, please read the accompanying Prescribing information<\/a> including the Boxed Warning about embryo-fetal toxicity. The Medication guide<\/a> also is available.<\/strong><\/p>\n\n<\/div>Has recently experienced worsening symptoms such as an increase in dyspnea and ankle edema<\/strong><\/h3><\/div>\n\n\n\n
Comorbidities:<\/strong><\/h3><\/div>\n\n\n\n
Medications:<\/strong><\/h3><\/div>\n\n\n\n
Activity level:<\/strong><\/h3><\/div>\n\n\n\n
Definitions:<\/strong><\/h3><\/div>\n\n\n\n
Indication<\/mark><\/strong><\/h2><\/div>
Selected Safety Information<\/mark><\/strong><\/h2><\/div>\n\n\n
WARNING: EMBRYO-FETAL TOXICITY<\/strong><\/h4><\/div>\n\n\n